JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
FREE Shipping for orders over $200
For this product you will need: BACTERIOSTATIC WATER For reconstitution.
Tb-500 is a man-made analogue of thymosin beta-4, a naturally occurring peptide produced by the thymus gland. Thymosin beta-4 is involved in the mediation of various biological processes, including cell differentiation, angiogenesis, tissue regeneration, wound healing and many other functions. It is made up of 43 amino acids and is present in different cells of the body including saliva, tears, wound fluid and blood. Most of the research points to the use of thymosin beta-4, a structurally similar compound to the TB-500, so synthetic TB-500 is expected to replicate similar results as Tβ4 [1].
Thymosin beta 4 was first isolated from the bovine thymus gland in the 1980s. After that, its synthetic version TB-500 was developed in 2010. Although being developed for veterinary purposes, people started using it in competitive horse racing, purposefully offering a distinct edge to treated horses. Consequently, its use got banned in horse racing and sports competitions. On our website, Tb-500 for sale is limited to educational and research purposes.
From Pubchem
Synonyms: QHK6Z47GTG, TB-500Molecular Formula: C38H68N10O14Molecular Weight: 889.0 g/molSequence: LKKTETQCAD Number: 885340-08-9PubChem CID: 62707662
TB-500 is known to be involved in the formation of new blood vessels; a process known as neovascularization. One research identifies Tβ4 as essential for the development of coronary vessels in mice. Further, the experiment reveals that the test compound triggers the growth of previously inactive epicardial explants and the differentiation of fibroblasts, muscle cells and endothelial cells [2].
A study was conducted to assess the mechanism behind the angiogenic effect of Tβ4. The test tubes containing endothelial cells were treated with Tβ4, along with inhibition of AKT and PI3Kα/Rho pathway. Further, in vivo studies using animal models (mice and rabbit) were done by injecting Tβ4 either along with the application of rAAV.AKT-dn or inhibition of Rho/PI3K/AKT pathways. Kindly note that AKT is a kinase protein crucial for the PI3/AKT pathway, and AKT-dn is a negative dominant form of AKT that disturbs its normal function. The results of this study found reduced formation of blood vessels with the inhibition of the PI3/AKT pathway, indicating its importance in mediating angiogenesis [3].
In a study, dystrophin-deficient mice, the mouse model of Duchenne muscular dystrophy, was treated with Tβ4 twice a week for six months. Results found an increased number of muscle-regenerating fibers in mice treated with Tβ4 as compared to untreated ones, indicating the potential of Tb-4 as an effective therapy for muscular dystrophy [4]. Furthermore, thymosin beta-4 promotes the survival of cardiomyocytes and repairs damage to the heart [5].
Various studies on animal models found that thymosin beta-4 can aid in wound healing and speed up recovery from injuries. One study in rats found Tb-4 to be effective in treating incisional wounds with minimal scarring. Moreover, it revealed that wounds treated with the peptide were narrow in width, had more organized collagen fibers and displayed red birefringence (an indication of mature connective tissues). While the untreated wounds displayed green birefringence, indicative of immature connective tissues, and had disorganized collagen fibers [6].
In a study, Tβ4 treatment six hours after traumatic brain injury lessened the size of cortical lesions and improved functional recovery in rats. While delayed treatment (24 hours after injury) didn’t alter the size of cortical lesions but significantly affected functional recovery in rats [7].
In a randomized double-blind, placebo-controlled, dose-escalation phase II trial, topical administration of Tβ4 improved wound healing in patients with venous ulcers. Furthermore, it found that a 0.03% dose of synthetic thymosin beta-4 helped 25% of the patients achieve full recovery whose wound size was small to moderate [8].
Thymosin beta 4 is believed to improve the recovery of injured tissues through its actin-sequestering properties. In the site of injury, thymosin B-4 binds with actin that promotes migration and differentiation of stem cells, resulting in the formation of new vessels that aid in wound healing. Further, it causes decreases in the number of myofibroblasts at the site of injury, thus reducing scar formation [9].
Thymosin beta-4 might be involved in the healing of the corneal surface. A study conducted on 72 subjects found 0.1% Tβ4 as an effective treatment for relieving symptoms of dry eyes with no adverse effects being reported [10].
In another study, nine patients with severe dry eyes were given Tβ4 eye drops or placebo six times per day for 28 days. Participants treated with the drug experienced a 35.3% reduction of ocular discomfort, 59.1% reduction of total corneal fluorescein staining and increased tear production as compared to those who received a placebo [11].
Various studies on animal models speak for the beneficial effect of Tb-4 in wound healing and angiogenesis. It hasn't been yet approved by the FDA for clinical use in humans. More research is needed to confirm the medicinal effects of TB-500 in humans. As an experimental drug, TB-500 purchase is limited for research, only buy Tb-500 if you are a licensed researcher.
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.